Skip to main content
Hit enter to search or ESC to close
Close Search
Menu
About us
Key figures
Our vision
Governance
Our CSR objectives
Membership
Platform
Microbiome Ecosystem Therapies
MET-N
MET-C
gutPrint®
cGMP manufacturing facility
Pipeline
Overview
Xervyteg®
MaaT033
MaaT034
MaaT03X
Scientific Publications
Patients & Healthcare Professionals
News
Corporate profile
Press Releases
Media Coverage
Posters
Videos
Investors
Stock information
Events & Presentations
Regulated information
Shareholders Meetings
CSR
Careers
Our values
Meet our people
Contact
Subscribe
Media
December 11, 2023: MaaT Pharma : dans la maladie aigüe du greffon contre l’hôte, MaaT Pharma annonce des résultats prometteurs – BFM Bourse (French only)
Date : 11/12/2023
To see the article, click here!
Previous Post
December 11, 2023: ASH 2023: microbiome-based therapy shows potential in graft-versus-host disease - EPR
Next Post
December 5, 2023: En Isère, au cœur du nouveau site de MaaT Pharma pour produire son traitement microbiote - L’Usine Nouvelle (French only)
Close Menu
About us
Key figures
Our vision
Governance
Our CSR objectives
Membership
Platform
Microbiome Ecosystem Therapies
MET-N
MET-C
gutPrint®
cGMP manufacturing facility
Pipeline
Overview
Xervyteg®
MaaT033
MaaT034
MaaT03X
Scientific Publications
Patients & Healthcare Professionals
News
Corporate profile
Press Releases
Media Coverage
Posters
Videos
Investors
Stock information
Events & Presentations
Regulated information
Shareholders Meetings
CSR
Careers
Our values
Meet our people
Contact
Subscribe
MaaT Pharma dans les médias
MaaT Pharma in the News
Devenez membre du club
Become a member of the club